Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
---|---|---|---|---|---|---|
MBX
|
James M Cornelius |
BUY
Conversion of derivative security
|
Direct | 102,082 Added 50.0% |
-
|
Sep 16
2024 |
GOOG
|
Sundar Pichai
Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct | 562 Added 0.13% |
-
|
Sep 16
2024 |
MBX
|
Frazier Life Sciences X, L.P. |
BUY
Conversion of derivative security
|
Direct | 3,927,774 Added 50.0% |
-
|
Sep 16
2024 |
MBX
|
Frazier Life Sciences X, L.P. |
BUY
Open market or private purchase
|
Direct | 625,000 Added 12.07% |
$10,000,000
$16.0 p/Share
|
Sep 16
2024 |
MBX
|
New Enterprise Associates 17, L.P. |
BUY
Conversion of derivative security
|
Direct | 3,114,486 Added 50.0% |
-
|
Sep 16
2024 |
MBX
|
New Enterprise Associates 17, L.P. |
BUY
Open market or private purchase
|
Direct | 500,000 Added 12.15% |
$8,000,000
$16.0 p/Share
|
Sep 16
2024 |
MBX
|
Orbimed Advisors LLC |
BUY
Conversion of derivative security
|
Indirect | 3,062,215 Added 0.0% |
-
|
Sep 16
2024 |
MBX
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect | 750,000 Added 0.0% |
$12,000,000
$16.0 p/Share
|
Sep 16
2024 |
MBX
|
Carl L Gordon |
BUY
Conversion of derivative security
|
Indirect | 3,062,215 Added 0.0% |
-
|
Sep 16
2024 |
MBX
|
Carl L Gordon |
BUY
Open market or private purchase
|
Indirect | 750,000 Added 0.0% |
$12,000,000
$16.0 p/Share
|
Sep 16
2024 |
MBX
|
Tiba Aynechi |
BUY
Conversion of derivative security
|
Indirect | 1,386,335 Added 0.0% |
-
|
Sep 16
2024 |
MBX
|
Tiba Aynechi |
BUY
Open market or private purchase
|
Indirect | 750,000 Added 0.0% |
$12,000,000
$16.0 p/Share
|
Sep 16
2024 |
YMAB
|
Thomas Gad
CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Indirect | 30,000 Reduced 0.0% |
$389,100
$12.97 p/Share
|
Sep 16
2024 |
MBX
|
P. Kent Hawryluk
President & CEO |
BUY
Conversion of derivative security
|
Direct | 283,846 Added 37.09% |
-
|
Sep 16
2024 |
MBX
|
P. Kent Hawryluk
President & CEO |
BUY
Conversion of derivative security
|
Indirect | 115,914 Added 0.0% |
-
|
Sep 16
2024 |
WYNN
|
Patricia Mulroy
Director |
SELL
Open market or private sale
|
Indirect | 2,650 Reduced 0.0% |
$208,634
$78.73 p/Share
|
Sep 16
2024 |
MBX
|
Patrick J Heron |
BUY
Conversion of derivative security
|
Indirect | 3,927,774 Added 0.0% |
-
|
Sep 16
2024 |
MBX
|
Patrick J Heron |
BUY
Open market or private purchase
|
Indirect | 625,000 Added 0.0% |
$10,000,000
$16.0 p/Share
|
Sep 16
2024 |
PLTR
|
Alexander C. Karp
Director |
SELL
Open market or private sale
|
Direct | 4,500,000 Reduced 41.16% |
$162,315,000
$36.07 p/Share
|
Sep 16
2024 |
PLTR
|
Alexander C. Karp
Director |
BUY
Conversion of derivative security
|
Direct | 4,500,000 Added 29.16% |
-
|
Sep 16
2024 |
FOUNU
|
Palantir Technologies Inc.
> 10% Shareholder |
SELL
Open market or private sale
|
Direct | 22,812 Reduced 0.26% |
$1,368
$0.06 p/Share
|
Sep 16
2024 |
OPEN
|
Megan D. Meyer
President, Sell Direct & Svcs. |
SELL
Open market or private sale
|
Direct | 65,750 Reduced 1.47% |
$142,020
$2.16 p/Share
|
Sep 16
2024 |
ML
|
Timmie Hong
Chief Product Officer |
SELL
Open market or private sale
|
Direct | 2,334 Reduced 2.16% |
$100,408
$43.02 p/Share
|
Sep 16
2024 |
OPEN
|
Carrie Wheeler
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 694,105 Reduced 4.52% |
$1,499,266
$2.16 p/Share
|
Sep 16
2024 |
OPEN
|
Sydney Schaub
Chief Legal Officer |
SELL
Open market or private sale
|
Direct | 77,376 Reduced 5.62% |
$167,132
$2.16 p/Share
|
Sep 16
2024 |
OPEN
|
Christina Schwartz
Officer |
SELL
Open market or private sale
|
Direct | 24,800 Reduced 3.16% |
$53,568
$2.16 p/Share
|
Sep 16
2024 |
PX
|
210 Capital, LLC |
SELL
Open market or private sale
|
Indirect | 129,462 Reduced 0.0% |
$1,363,234
$10.53 p/Share
|
Sep 16
2024 |
ATI
|
Robert S Wetherbee
Executive Chairman |
SELL
Open market or private sale
|
Direct | 25,000 Reduced 4.66% |
$1,540,250
$61.61 p/Share
|
Sep 16
2024 |
GOOG
|
Frances Arnold |
BUY
Grant, award, or other acquisition
|
Direct | 8 Added 0.43% |
-
|
Sep 16
2024 |
APPN
|
Abdiel Capital Advisors, LP |
BUY
Open market or private purchase
|
Indirect | 1,486 Added 0.0% |
$49,008
$32.98 p/Share
|
Sep 16
2024 |
TMDX
|
Waleed H Hassanein
President & CEO |
SELL
Open market or private sale
|
Direct | 8,625 Reduced 12.27% |
$1,326,870
$153.84 p/Share
|
Sep 16
2024 |
TMDX
|
Waleed H Hassanein
President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct | 8,625 Added 10.93% |
$114,540
$13.28 p/Share
|
Sep 16
2024 |
BTAI
|
Javier Rodriguez
Officer |
SELL
Open market or private sale
|
Direct | 345 Reduced 3.64% |
$238
$0.69 p/Share
|
Sep 16
2024 |
VRNT
|
Elan Moriah
President |
SELL
Open market or private sale
|
Direct | 7,160 Reduced 4.89% |
$185,086
$25.85 p/Share
|
Sep 16
2024 |
BTAI
|
Richard I Steinhart
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 356 Reduced 5.43% |
$245
$0.69 p/Share
|
Sep 16
2024 |
BTAI
|
Vimal Mehta
CEO and President |
SELL
Open market or private sale
|
Direct | 1,982 Reduced 3.69% |
$1,367
$0.69 p/Share
|
Sep 16
2024 |
BTAI
|
Frank Yocca
Chief Scientific Officer |
SELL
Open market or private sale
|
Direct | 355 Reduced 2.44% |
$244
$0.69 p/Share
|
Sep 16
2024 |
VRNT
|
Dan Bodner
Chairman & CEO |
SELL
Open market or private sale
|
Direct | 16,932 Reduced 2.78% |
$437,692
$25.85 p/Share
|
Sep 16
2024 |
MBX
|
Wellington Biomedical Innovation Master Investors (Cayman) Ii L.P. |
BUY
Conversion of derivative security
|
Direct | 1,790,122 Added 50.0% |
-
|
Sep 16
2024 |
VRNT
|
Peter Fante
Chief Administrative Officer |
SELL
Open market or private sale
|
Direct | 6,330 Reduced 6.48% |
$163,630
$25.85 p/Share
|
Sep 16
2024 |
DBX
|
Timothy Regan
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 400 Reduced 0.08% |
$10,000
$25.0 p/Share
|
Sep 16
2024 |
BTAI
|
Matthew T. Wiley
Chief Commercial Officer |
SELL
Open market or private sale
|
Direct | 215 Reduced 5.06% |
$148
$0.69 p/Share
|
Sep 16
2024 |
VRNT
|
Grant A Highlander
Chief Financial Officer |
SELL
Open market or private sale
|
Direct | 3,389 Reduced 2.52% |
$87,605
$25.85 p/Share
|
Sep 16
2024 |
BTAI
|
Vincent O'Neill
Officer |
SELL
Open market or private sale
|
Direct | 138 Reduced 3.41% |
$95
$0.69 p/Share
|
Sep 16
2024 |
ACEL
|
David W. Ruttenberg
Director |
SELL
Open market or private sale
|
Indirect | 25,000 Reduced 0.0% |
$292,000
$11.68 p/Share
|
Sep 16
2024 |
CME
|
Terrence A Duffy
Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct | 27,456 Added 22.44% |
$5,999,959
$218.53 p/Share
|
Sep 16
2024 |
CME
|
Julie Holzrichter
Sr MD Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct | 3,604 Added 8.18% |
$787,582
$218.53 p/Share
|
Sep 16
2024 |
CME
|
Derek Sammann
Sr MD Gl Hd Commodity & Option |
BUY
Grant, award, or other acquisition
|
Direct | 3,604 Added 23.41% |
$787,582
$218.53 p/Share
|
Sep 16
2024 |
CME
|
Julie Winkler
Sr MD Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct | 3,604 Added 9.72% |
$787,582
$218.53 p/Share
|
Sep 16
2024 |
CME
|
Jack J Tobin
MD Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct | 852 Added 3.49% |
$186,187
$218.53 p/Share
|
Sep 16
2024 |